Search - tctmd.com

Displaying 81 - 100 of 230

Sort: Relevancy | Date

News Conference News ACC 2023

STOP-CA: Atorvastatin Curbs Heart Function Decline During Chemotherapy

L.A. McKeown

March 04, 2023

News Conference News ACC 2023

Clear CVD Benefit With Bempedoic Acid: CLEAR Outcomes

Michael O'Riordan

March 04, 2023

News Conference News ACC 2023

By Mid-Century, More Hot Days Will Spur More CV Deaths

Caitlin E. Cox

March 02, 2023

News Opinion Editor's Corner ACC 2023

What’s Going to Be Hot at ACC/WCC 2023?

Shelley Wood

February 27, 2023

News Conference News ACC 2022

No Difference in 1-Year QoL Between FFR-Guided PCI and CABG: FAME-3

Michael O'Riordan

April 13, 2022

News Conference News ACC 2022

DIAMOND Shines Bright on Patiromer for Curbing Hyperkalemia in HFrEF

L.A. McKeown

April 08, 2022

News Conference News ACC 2022

SPYRAL HTN-ON MED at 3 Years: Renal Denervation’s BP Impact Endures

Todd Neale

April 08, 2022

News Conference News ACC 2022

Modest Effects, Safety Concerns Plague Vupanorsen in TRANSLATE-TIMI 70

Michael O'Riordan

April 07, 2022

News Conference News ACC 2022

QoL Gains Within 15 Days in Acute HF With Empagliflozin: EMPULSE Analysis

L.A. McKeown

April 07, 2022

News Conference News ACC 2022

POISE-3: Two Perioperative BP Strategies Give Similar Results in Noncardiac Surgery

Todd Neale

April 06, 2022

News Conference News ACC 2022

FLAVOUR: FFR as Good as IVUS for Intermediate Coronary Stenoses

Michael O'Riordan

April 06, 2022

News Conference News ACC 2022

ADAPT-TAVR: Edoxaban No Better Than DAPT After TAVI

Todd Neale

April 05, 2022

Presentation ACC 2022

A Cluster-Randomized PRagmatic Trial Aimed At ImprOving Use Of Guideline Directed Medical Therapy In OutPatienTs With Heart Failure: PROMPT-HF

Presenter: Tariq Ahmad

April 04, 2022

Presentation ACC 2022

The Effects Of A Hypotension-avoidance Strategy Versus A Hypertension-avoidance Strategy In Patients Undergoing Noncardiac Surgery

Presenter: Maura Marcucci

April 04, 2022

Presentation ACC 2022

SODIUM-HF: Study Of Dietary Intervention Under 100 Mmol In Heart Failure

Presenter: Justin Ezekowitz

April 04, 2022

Presentation ACC 2022

Long Term Efficacy and Safety of Renal Denervation on Blood Pressure in Patients on Antihypertension Medications: 3-Year Outcomes from the SPYRAL HTN-ON MED Trial

Presenter: Felix Mahfoud

April 04, 2022

Presentation ACC 2022

TRANSLATE-TIMI 70

Presenter: Brian Bergmark

April 04, 2022

Presentation ACC 2022

A Single Ascending Dose Study of an siRNA Targeting Lipoprotein(a)

Presenter: Steven E. Nissen

April 04, 2022

News Conference News ACC 2022

Most Infected Cardiac Implanted Electronic Devices Not Removed Fast Enough

Michael O'Riordan

April 04, 2022

News Conference News ACC 2022

APOLLO: Novel siRNA Injectable Cuts Lp(a) by Nearly 100% in Small Study

Michael O'Riordan

April 03, 2022

Advertisement

STOP-CA: Atorvastatin Curbs Heart Function Decline During Chemotherapy

Clear CVD Benefit With Bempedoic Acid: CLEAR Outcomes

By Mid-Century, More Hot Days Will Spur More CV Deaths

What’s Going to Be Hot at ACC/WCC 2023?

No Difference in 1-Year QoL Between FFR-Guided PCI and CABG: FAME-3

DIAMOND Shines Bright on Patiromer for Curbing Hyperkalemia in HFrEF

SPYRAL HTN-ON MED at 3 Years: Renal Denervation’s BP Impact Endures

Modest Effects, Safety Concerns Plague Vupanorsen in TRANSLATE-TIMI 70

QoL Gains Within 15 Days in Acute HF With Empagliflozin: EMPULSE Analysis

POISE-3: Two Perioperative BP Strategies Give Similar Results in Noncardiac Surgery

FLAVOUR: FFR as Good as IVUS for Intermediate Coronary Stenoses

ADAPT-TAVR: Edoxaban No Better Than DAPT After TAVI

A Cluster-Randomized PRagmatic Trial Aimed At ImprOving Use Of Guideline Directed Medical Therapy In OutPatienTs With Heart Failure: PROMPT-HF

The Effects Of A Hypotension-avoidance Strategy Versus A Hypertension-avoidance Strategy In Patients Undergoing Noncardiac Surgery

SODIUM-HF: Study Of Dietary Intervention Under 100 Mmol In Heart Failure

Long Term Efficacy and Safety of Renal Denervation on Blood Pressure in Patients on Antihypertension Medications: 3-Year Outcomes from the SPYRAL HTN-ON MED Trial

TRANSLATE-TIMI 70

A Single Ascending Dose Study of an siRNA Targeting Lipoprotein(a)

Most Infected Cardiac Implanted Electronic Devices Not Removed Fast Enough

APOLLO: Novel siRNA Injectable Cuts Lp(a) by Nearly 100% in Small Study

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content